cp wire

CP Wire Articles

OrphoMed's IBS-D Candidate ORP-101 Receives Fast Track Designation

In June of 2017, OrphoMed announced that they had closed a $39 Million series A round to accelerate development of their lead candidate, ORP-101, IBS-D. On 4/25/18 they announced that the FDA has... read more

Wed, 04/25/18 - 09:18 am
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study
  • In SELECT-SUNRISE study, upadacitinib met the primary endpoint of ACR20 (An ACR20 score means that a person's RA has improved by 20%) across all doses (7.5 mg, 15 mg, 30 mg, once-daily) at... read more
Wed, 04/25/18 - 09:07 am
New Data For Alder BioPharmaceuticals' Eptinezumab Shows Long-Term Reduction in Episodic Migraine

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), announced on 4/24/18 that new twelve-month data from its PROMISE 1 Phase 3 clinical trial in episodic migraine patients. The data demonstrated that... read more

Tue, 04/24/18 - 11:52 pm
Mirati Therapeutics Announces Positive Results in Immuno-Oncology Combination Trials

Mirati Therapeutics, Inc. (Nasdaq: MRTX) (the Company or Mirati), On 4/24/18 provided a progress update on its lead development programs and announced updated, positive clinical trial data for... read more

Tue, 04/24/18 - 11:17 pm
Interview With Hatch-Waxman Expert Kurt Karst

                 
Kurt R. Karst provides regulatory counsel to pharmaceutical manufacturers on Hatch-Waxman patent and exclusivity, drug development, pediatric testing, and orphan drugs. He... read more

Tue, 04/24/18 - 07:50 pm

Pages